EUSA Pharma, Inc.

1717 Langhorne-Newtown Road,
Langhorne, Pennsylvania 19047
United States,
(215)230-9620
www.eusapharma.com

EUSA Pharma, Inc., is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (0.4/yr) # - - - 1 - 1 2
vol $115M $115M
Sell (0.0/yr) # - - - - - - 0
  2

Top M&A Advisors

Financial Deals
Join to Access.
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest SYLVANT
$115M (2018-07-18)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

EUSA Pharma was acquired by Jazz Pharmaceuticals on April 30, 2012.

EUSA Pharma has acquired 2 companies of its own, including 2 in the last 5 years.

EUSA Pharma’s largest acquisition to date was in 2018, when it acquired SYLVANT for $115M. EUSA Pharma has acquired in 2 different US states. The Company’s most targeted sectors include life science (100%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 407 life science companies that have made at least 1 acquisition, 14 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 30 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 6 platform acquisitions.

Join Mergr and gain access to EUSA Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.5K Private Equity Firms
  • 123K M&A Transactions
  • 132K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.9K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.